Focused Ultrasound Targets Hippocampus to Reverse Depression-Like Brain Inflammation

Depression remains undertreated globally, with many patients failing to respond adequately to existing medications. Non-invasive brain stimulation techniques are gaining attention as complementary or alternative options, and low-intensity focused ultrasound (LIFU) has emerged as a particularly promising tool because of its ability to reach deep brain structures without surgery or ionizing radiation.

In this study, researchers used the chronic social defeat stress (CSDS) mouse model — a well-validated preclinical analog of human depression — to test whether seven consecutive days of LIFU directed at the right hippocampus could reverse stress-induced pathology. Male mice subjected to CSDS showed classic depression-like and anxiety-like behaviors assessed via the forced swim test and open field test.

LIFU intervention significantly improved performance on both behavioral measures. At the molecular level, the treatment markedly reduced protein expression of Notch1, its ligand Jagged1, and the downstream transcription factor Hes1 — key nodes of the Notch1 inflammatory signaling pathway. This suppression was accompanied by lower levels of NF-κB and interleukin-6, two central mediators of neuroinflammation.

Critically, reduced inflammation coincided with enhanced neurogenesis in the dentate gyrus of the hippocampus, suggesting that dampening neuroinflammation creates a permissive environment for new neuron formation. The authors propose a mechanistic framework in which hippocampus-targeted LIFU inhibits Notch1-driven inflammation, which in turn unlocks neurogenic capacity and drives behavioral recovery.

The findings are compelling but remain preclinical, conducted only in male rodents. Translation to human patients will require dose optimization, safety profiling across sexes and ages, and clinical trials. Nonetheless, this study meaningfully advances the mechanistic rationale for LIFU as a novel, drug-free mood disorder therapy.